Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Sutter

Showing results (101-110 of 179) with videos related to

Pageof 18
Sort By:
Vaccines|January 8, 2025
Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in HumansAlina Tscherne, Georgia Kalodimou, Alexandra Kupke, et al.
The Journal of General Virology|September 1, 2025
Robust polyfunctional CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses in HLA-A*0201/DR1 transgenic mice following vaccination with modified vaccinia virus Ankara-based vaccines delivering Lassa virus glycoprotein or nucleoproteinAlina Tscherne, Georgia Kalodimou, Sylvia Jany, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 6, 2011
Cytosolic DNA triggers mitochondrial apoptosis via DNA damage signaling proteins independently of AIM2 and RNA polymerase IIIMichael Wenzel, Michael Wunderlich, Robert Besch, et al.
AIDS Research and Human Retroviruses|July 3, 2007
Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAARTAntonio Cosma, Rashmi Nagaraj, Caroline Staib, et al.
Journal of Virology|July 11, 2014
Chemokine (C-C Motif) receptor 1 is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus AnkaraPhilip J R Price, Bruno Luckow, Lino E Torres-Domínguez, et al.
Cellular & Molecular Immunology|February 13, 2018
Application of light sheet microscopy for qualitative and quantitative analysis of bronchus-associated lymphoid tissue in miceDavid Twapokera Mzinza, Henrike Fleige, Kristin Laarmann, et al.
NPJ Vaccines|October 17, 2018
Generation of therapeutic antisera for emerging viral infectionsRebecca Schmidt, Lea C Beltzig, Bevan Sawatsky, et al.
Journal of Virology|May 29, 2015
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike GlycoproteinAsisa Volz, Alexandra Kupke, Fei Song, et al.
Viruses|July 19, 2014
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesArwen F Altenburg, Joost H C M Kreijtz, Rory D de Vries, et al.
Vaccines|January 26, 2024
Immunity to Tick-Borne Encephalitis Virus NS3 Protein Induced with a Recombinant Modified Vaccinia Virus Ankara Fails to Afford Mice Protection against TBEV InfectionMareike Kubinski, Jana Beicht, Thomas Gerlach, et al.
Pageof 18

Showing results (101-110 of 179) with videos related to

Sort By:
Pageof 18
Vaccines|January 8, 2025
Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in HumansAlina Tscherne, Georgia Kalodimou, Alexandra Kupke, et al.
The Journal of General Virology|September 1, 2025
Robust polyfunctional CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses in HLA-A*0201/DR1 transgenic mice following vaccination with modified vaccinia virus Ankara-based vaccines delivering Lassa virus glycoprotein or nucleoproteinAlina Tscherne, Georgia Kalodimou, Sylvia Jany, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 6, 2011
Cytosolic DNA triggers mitochondrial apoptosis via DNA damage signaling proteins independently of AIM2 and RNA polymerase IIIMichael Wenzel, Michael Wunderlich, Robert Besch, et al.
AIDS Research and Human Retroviruses|July 3, 2007
Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAARTAntonio Cosma, Rashmi Nagaraj, Caroline Staib, et al.
Journal of Virology|July 11, 2014
Chemokine (C-C Motif) receptor 1 is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus AnkaraPhilip J R Price, Bruno Luckow, Lino E Torres-Domínguez, et al.
Cellular & Molecular Immunology|February 13, 2018
Application of light sheet microscopy for qualitative and quantitative analysis of bronchus-associated lymphoid tissue in miceDavid Twapokera Mzinza, Henrike Fleige, Kristin Laarmann, et al.
NPJ Vaccines|October 17, 2018
Generation of therapeutic antisera for emerging viral infectionsRebecca Schmidt, Lea C Beltzig, Bevan Sawatsky, et al.
Journal of Virology|May 29, 2015
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike GlycoproteinAsisa Volz, Alexandra Kupke, Fei Song, et al.
Viruses|July 19, 2014
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesArwen F Altenburg, Joost H C M Kreijtz, Rory D de Vries, et al.
Vaccines|January 26, 2024
Immunity to Tick-Borne Encephalitis Virus NS3 Protein Induced with a Recombinant Modified Vaccinia Virus Ankara Fails to Afford Mice Protection against TBEV InfectionMareike Kubinski, Jana Beicht, Thomas Gerlach, et al.
Pageof 18